JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference

Zacks 03:30

Johnson & Johnson Ratings Put On CreditWatch Negative by S&P Global

MT Newswires02:51

S&P has placed Johnson & Johnson (JNJ.US) on negative credit watch.

The rating agency S&P has placed Johnson & Johnson (JNJ.US) on a credit watch with a negative outlook, primarily due to the company's acquisition of the mental health drug developer Intra-Cellular Therapies for nearly 15 billion USD. S&P believes that this acquisition will raise Johnson & Johnson's adjusted leverage ratio to about 1.4 times, exceeding the downgrade trigger of 1 time set by S&P's ratings. Johnson & Johnson added that it expects its adjusted leverage ratio to decline to 1.1 times by the end of 2025 and to below 1 time by the end of 2026.

AASTOCKS02:31

Intra-Cellular Therapies Analyst Ratings

Benzinga00:35 · Ratings

Daily short sale tracking: Maplebear's short volume increased by 9 million, with a short sale ratio of 38%

Maplebear(CART.US) ranked top of the list had the largest change in short volume (9.35 million shares), and the short volume ratio of Royal Bank of Canada(RY.US) reached 72.4%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.

Futu NewsJan 14 22:00

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer

Zacks Jan 14 21:05